Bristol-Myers Squibb (BMS) recently revealed that a late-stage clinical trial for the expanded use of its medication, Cobenfy, did not yield statistically significant results.
According to reports, the medication, which was approved last year, failed to meet its primary objective in this trial involving schizophrenia patients who did not improve with current antipsychotic therapies.
At week six of the trial, the medication demonstrated a 2 percentage point drop in a symptom severity measure compared to a placebo.
Bristol-Myers has completed the analysis of all trial data and intends to present the findings in depth at a future academic conference.
